Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Liver Cirrhosis

Free Subscription Articles published in N Engl J Med Retrieve available abstracts of 32 articles: HTML format

Single Articles

May 2024
1. KOWDLEY KV, Levy C, Jones D
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
   N Engl J Med. 2024;390:1935-1936.
   PubMed    
   
   
   
2. HIRSCHFIELD GM, Kremer AE, Levy C
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis. Reply.
   N Engl J Med. 2024;390:1934-1935.
   PubMed    
   
   
   
3. IJICHI H
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:1934.
   PubMed    
   
   
   
4. AREVALO-CANAS C, Arevalo-Serrano J
   Phase 3 Trials of Elafibranor and Seladelpar for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:1933-1934.
   PubMed    
   
   
   
5. HARRISON SA, Taub R
   A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
   N Engl J Med. 2024;390:1632-1633.
   PubMed    
   
   
   
6. SABET A
   A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis.
   N Engl J Med. 2024;390:1632.
   PubMed    
   
   
   February 2024
7. SCHNABL B
   PPAR Agonists in Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:855-858.
   PubMed    
   
   
   
8. HIRSCHFIELD GM, Bowlus CL, Mayo MJ, Kremer AE, et al
   A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:783-794.
   PubMed     Abstract available
   
   
   
9. ASSIS DN
   Advancing Second-Line Treatment for Primary Biliary Cholangitis.
   N Engl J Med. 2024;390:853-854.
   PubMed    
   
   
   
10. HARRISON SA, Bedossa P, Guy CD, Schattenberg JM, et al
    A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
    N Engl J Med. 2024;390:497-509.
    PubMed     Abstract available
    
    
    November 2023
11. ROBBINS J, Halegoua-DeMarzio D, Basu Mallick A, Vijayvergia N, et al
    Liver Transplantation in a Woman with Mahvash Disease.
    N Engl J Med. 2023;389:1972-1978.
    PubMed     Abstract available
    
    
    
12. KOWDLEY KV, Bowlus CL, Levy C, Akarca US, et al
    Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
    N Engl J Med. 2023 Nov 13. doi: 10.1056/NEJMoa2306185.
    PubMed     Abstract available
    
    
    February 2023
13. NADIM MK, Garcia-Tsao G
    Acute Kidney Injury in Patients with Cirrhosis.
    N Engl J Med. 2023;388:733-745.
    PubMed    
    
    
    December 2022
14. BATALLER R, Arab JP, Shah VH
    Alcohol-Associated Hepatitis.
    N Engl J Med. 2022;387:2436-2448.
    PubMed    
    
    
    August 2022
15. STRNAD P, Mandorfer M, Choudhury G, Griffiths W, et al
    Fazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency.
    N Engl J Med. 2022;387:514-524.
    PubMed     Abstract available
    
    
    January 2022
16. PATEL A, Tillman BF
    Spur-Cell Hemolytic Anemia.
    N Engl J Med. 2022;386:e6.
    PubMed    
    
    
    October 2021
17. SANYAL AJ, Van Natta ML, Clark J, Neuschwander-Tetri BA, et al
    Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease.
    N Engl J Med. 2021;385:1559-1569.
    PubMed     Abstract available
    
    
    
18. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    PubMed     Abstract available
    
    
    September 2021
19. CHANDRA A, Bhattacharjee MS
    Kayser-Fleischer Rings in Wilson's Disease.
    N Engl J Med. 2021;385:e46.
    PubMed    
    
    
    
20. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis. Reply.
    N Engl J Med. 2021;385:1151-1152.
    PubMed    
    
    
    
21. HAIDAR G, Singh N
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;385:1150-1151.
    PubMed    
    
    
    June 2021
22. BAJAJ JS, Kamath PS, Reddy KR
    The Evolving Challenge of Infections in Cirrhosis.
    N Engl J Med. 2021;384:2317-2330.
    PubMed    
    
    
    
23. WONG F, Curry MP, Sanyal AJ
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
24. CHINA L, Freemantle N, O'Brien A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis. Reply.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
25. RATHI S, Kalantri A, Kalantri S
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
26. CHAUHAN A, Sharma S, Saraya A
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    
27. ELFEKI MA, O'Shea R, Carey WD
    Randomized Trials of Interventions for Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:e90.
    PubMed    
    
    
    March 2021
28. CACOUB P, Saadoun D
    Extrahepatic Manifestations of Chronic HCV Infection.
    N Engl J Med. 2021;384:1038-1052.
    PubMed    
    
    
    
29. GARCIA-TSAO G
    Terlipressin and Intravenous Albumin in Advanced Cirrhosis - Friend and Foe.
    N Engl J Med. 2021;384:869-871.
    PubMed    
    
    
    
30. CHINA L, Freemantle N, Forrest E, Kallis Y, et al
    A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis.
    N Engl J Med. 2021;384:808-817.
    PubMed     Abstract available
    
    
    
31. WONG F, Pappas SC, Curry MP, Reddy KR, et al
    Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
    N Engl J Med. 2021;384:818-828.
    PubMed     Abstract available
    
    
    November 2020
32. NEWSOME PN, Buchholtz K, Cusi K, Linder M, et al
    A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
    N Engl J Med. 2020 Nov 13. doi: 10.1056/NEJMoa2028395.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Cirrhosis is free of charge.